Sangamo Therapeutics (NASDAQ:SGMO) Upgraded at StockNews.com

Sangamo Therapeutics (NASDAQ:SGMO) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Thursday.

Several other research firms have also issued reports on SGMO. Barclays lifted their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, November 14th.

Sangamo Therapeutics Stock Down 1.7 %

Shares of SGMO opened at $2.26 on Thursday. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The stock has a market cap of $471.55 million, a PE ratio of -3.01 and a beta of 1.10. The business’s 50-day moving average price is $1.54 and its 200-day moving average price is $0.96.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The business had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. During the same quarter in the prior year, the firm posted ($0.34) EPS. Analysts expect that Sangamo Therapeutics will post -0.52 earnings per share for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC increased its stake in Sangamo Therapeutics by 58.8% in the second quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company’s stock valued at $1,479,000 after acquiring an additional 1,528,600 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Sangamo Therapeutics by 14.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company’s stock worth $1,853,000 after purchasing an additional 272,123 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Sangamo Therapeutics by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after purchasing an additional 57,125 shares during the last quarter. State Street Corp raised its holdings in shares of Sangamo Therapeutics by 28.0% during the 3rd quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 145,400 shares in the last quarter. Finally, Marshall Wace LLP lifted its position in Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 207,476 shares during the last quarter. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.